Development of a COVID-19 vaccine based on the receptor binding domain displayed on virus-like particles

The recently ermerging disease COVID-19 is caused by the new SARS-CoV-2 virus first detected in the city of Wuhan, China. From there it has been rapidly spreading inside and outside China. With initial death rates around 4%, COVID-19 patients at longer distances from Wuhan showed reduced mortality as was previously observed for the SARS coronavirus. However, the new coronavirus spreads more strongly, as it sheds long before onset of symptoms or may be transmitted by people without symptoms. Rapid development of a protective vaccine against COVID-19 is therefore of paramount importance. Here we demonstrate that recombinantly expressed receptor binding domain (RBD) of the spike protein homologous to SARS binds to ACE2, the viral receptor. Higly repetitive display of RBD on immunologically optimized virus-like particles derived from cucumber mosaic virus resulted in a vaccine candidate (RBD-CuMVTT) that induced high levels of specific antibodies in mice which were able to block binding of spike protein to ACE2 and potently neutralized the SARS-CoV-2 virus in vitro.

[1]  D. Speiser,et al.  COVID-19: Mechanisms of Vaccination and Immunity , 2020, Vaccines.

[2]  Nguyen H. Tran,et al.  Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial , 2020, The Lancet.

[3]  M. Nussenzweig,et al.  Structures of Human Antibodies Bound to SARS-CoV-2 Spike Reveal Common Epitopes and Recurrent Features of Antibodies , 2020, Cell.

[4]  E. Bentivegna,et al.  New IgM seroconversion and positive RT‐PCR test after exposure to the virus in recovered COVID‐19 patient , 2020, Journal of medical virology.

[5]  M. Bachmann,et al.  The 3Ds in virus‐like particle based‐vaccines: “Design, Delivery and Dynamics” , 2020, Immunological reviews.

[6]  William J. Liu,et al.  A human neutralizing antibody targets the receptor-binding site of SARS-CoV-2 , 2020, Nature.

[7]  Linqi Zhang,et al.  Human neutralizing antibodies elicited by SARS-CoV-2 infection , 2020, Nature.

[8]  M. Tay,et al.  The trinity of COVID-19: immunity, inflammation and intervention , 2020, Nature Reviews Immunology.

[9]  M. Diamond,et al.  TMPRSS2 and TMPRSS4 mediate SARS-CoV-2 infection of human small intestinal enterocytes , 2020, bioRxiv.

[10]  Lei Liu,et al.  Potent human neutralizing antibodies elicited by SARS-CoV-2 infection , 2020, bioRxiv.

[11]  B. Cowie,et al.  Breadth of concomitant immune responses prior to patient recovery: a case report of non-severe COVID-19 , 2020, Nature Medicine.

[12]  K. Yuen,et al.  Clinical Characteristics of Coronavirus Disease 2019 in China , 2020, The New England journal of medicine.

[13]  Jianguo Wu,et al.  Composition and divergence of coronavirus spike proteins and host ACE2 receptors predict potential intermediate hosts of SARS‐CoV‐2 , 2020, Journal of medical virology.

[14]  Zunyou Wu,et al.  Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention. , 2020, JAMA.

[15]  W. Liang,et al.  Clinical characteristics of 2019 novel coronavirus infection in China , 2020, medRxiv.

[16]  M. Vogel,et al.  Vaccine against peanut allergy based on engineered Virus-Like-Particles displaying single major peanut allergens. , 2019, The Journal of allergy and clinical immunology.

[17]  T. Kündig,et al.  Treating insect‐bite hypersensitivity in horses with active vaccination against IL‐5 , 2018, The Journal of allergy and clinical immunology.

[18]  M. Vogel,et al.  Interaction of Viral Capsid-Derived Virus-Like Particles (VLPs) with the Innate Immune System , 2018, Vaccines.

[19]  M. Bachmann,et al.  Vaccination against IL-31 for the treatment of atopic dermatitis in dogs. , 2018, The Journal of allergy and clinical immunology.

[20]  Salemiz Sandoval,et al.  Pseudotyped Lentiviral Vectors: One Vector, Many Guises. , 2017, Human gene therapy methods.

[21]  D. Stuart,et al.  Incorporation of tetanus-epitope into virus-like particles achieves vaccine responses even in older recipients in models of psoriasis, Alzheimer’s and cat allergy , 2017, npj Vaccines.

[22]  M. Bachmann,et al.  Innate Immunity Mediates Follicular Transport of Particulate but Not Soluble Protein Antigen , 2012, The Journal of Immunology.

[23]  G. Jennings,et al.  Therapeutic vaccines for chronic diseases: successes and technical challenges , 2011, Philosophical Transactions of the Royal Society B: Biological Sciences.

[24]  Martin F. Bachmann,et al.  Vaccine delivery: a matter of size, geometry, kinetics and molecular patterns , 2010, Nature Reviews Immunology.

[25]  Marianne Manchester,et al.  Viral nanoparticles and virus‐like particles: platforms for contemporary vaccine design , 2010, Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology.

[26]  F. Plummer,et al.  Neutralizing epitopes of the SARS-CoV S-protein cluster independent of repertoire, antigen structure or mAb technology , 2010, mAbs.

[27]  Stephen W. Martin,et al.  Complement receptors regulate differentiation of bone marrow plasma cell precursors expressing transcription factors Blimp-1 and XBP-1 , 2005, The Journal of experimental medicine.

[28]  Shibo Jiang,et al.  Receptor-binding domain of SARS-CoV spike protein induces highly potent neutralizing antibodies: implication for developing subunit vaccine , 2004, Biochemical and Biophysical Research Communications.

[29]  B. Murphy,et al.  An efficient method to make human monoclonal antibodies from memory B cells: potent neutralization of SARS coronavirus , 2004, Nature Medicine.

[30]  Wenhui Li,et al.  A 193-Amino Acid Fragment of the SARS Coronavirus S Protein Efficiently Binds Angiotensin-converting Enzyme 2* , 2004, Journal of Biological Chemistry.

[31]  John L. Sullivan,et al.  Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus , 2003, Nature.

[32]  D. Lowy,et al.  Conjugation of a self-antigen to papillomavirus-like particles allows for efficient induction of protective autoantibodies. , 2001, The Journal of clinical investigation.

[33]  R. Zinkernagel,et al.  The influence of antigen organization on B cell responsiveness. , 1993, Science.

[34]  Ming-jie Li,et al.  Generation of High-Titer Pseudotyped Lentiviral Vectors. , 2019, Methods in molecular biology.

[35]  R. Zinkernagel,et al.  Neutralizing antiviral B cell responses. , 1997, Annual review of immunology.